X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NXP004
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NXP004
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
NXP004 showed a dose-dependent reduction in the secretion of several key ECM components.These data suggest NXP004 compares favourably to current standard of care with regard to anti-fibrotic activity in this model.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RXC006
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RXC006
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: $377.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 04, 2020
Details:
Under the terms of the exclusive global agreement, AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RXC007
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2020
Details:
Preclinical data with compounds from Redx’s ROCK2 programme have demonstrated robust anti-fibrotic effects in a range of industry-standard in vivo models.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
